Oculis Holding AG
Business
Oculis Holding AG is a late-stage biopharmaceutical company developing innovative therapeutics for neuro-ophthalmic and ophthalmic diseases. The company's pipeline includes three clinical-stage candidates: OCS-01 (an eye drop for diabetic macular edema using proprietary OPTIREACH technology), Licaminlimab (an anti-TNFα biologic for dry eye disease with a precision medicine approach), and Privosegtor (a neuroprotective agent for optic neuritis and non-arteritic anterior ischemic optic neuropathy). Oculis operates in Switzerland, the U.S., and Iceland, with all three lead candidates in Phase 2/3 or Phase 3 clinical trials targeting unmet needs in ophthalmology and neuro-ophthalmology.
Summary from 20-F filed 2026-03-04
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-98.96M |
| Total assets | $235.96M |
| Total liabilities | $39.89M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Oculis Holding AG's CIK number?
Oculis Holding AG's SEC CIK number is 0001953530 (1953530). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Oculis Holding AG's SEC filings?
All of Oculis Holding AG's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.